255 related articles for article (PubMed ID: 33192110)
1. Carcinoid Heart Disease: How to Diagnose and Treat in 2020?
Bober B; Saracyn M; Kołodziej M; Kowalski Ł; Deptuła-Krawczyk E; Kapusta W; Kamiński G; Mozenska O; Bil J
Clin Med Insights Cardiol; 2020; 14():1179546820968101. PubMed ID: 33192110
[TBL] [Abstract][Full Text] [Related]
2. Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.
Das S; Stockton SS; Hassan SA
Oncologist; 2023 Jul; 28(7):575-583. PubMed ID: 37209415
[TBL] [Abstract][Full Text] [Related]
3. Carcinoid syndroma - diagnosis and management.
Kiňová S; Koreň M
Vnitr Lek; 2021; 67(5):310-314. PubMed ID: 35459398
[TBL] [Abstract][Full Text] [Related]
4. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
5. Rare Presentation of a Metastatic Pancreatic Neuroendocrine Neoplasm Presenting with Atrial Flutter.
Fragkou PC; Papadopoulos IA; Papadopoulos A; Kontoveros EA; Kaltsas G; Vassilara F
Eur J Case Rep Intern Med; 2021; 8(1):002216. PubMed ID: 33585343
[TBL] [Abstract][Full Text] [Related]
6. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
8. Use of perioperative telotristat in a patient with carcinoid heart disease.
Flynn M; Noss C; Miller R; Adams C; Ruether D; Chan D; Pasieka J; Lithgow K
Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38377684
[TBL] [Abstract][Full Text] [Related]
9. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
[TBL] [Abstract][Full Text] [Related]
10. Carcinoid heart disease.
Gustafsson BI; Hauso O; Drozdov I; Kidd M; Modlin IM
Int J Cardiol; 2008 Oct; 129(3):318-24. PubMed ID: 18571250
[TBL] [Abstract][Full Text] [Related]
11. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
12. Ileal neuroendocrine tumors and heart: not only valvular consequences.
Calissendorff J; Maret E; Sundin A; Falhammar H
Endocrine; 2015 Apr; 48(3):743-55. PubMed ID: 25319177
[TBL] [Abstract][Full Text] [Related]
13. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome.
Clement D; Ramage J; Srirajaskanthan R
J Oncol; 2020; 2020():8341426. PubMed ID: 32322270
[TBL] [Abstract][Full Text] [Related]
14. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid Heart Disease in Patients With Bronchopulmonary Carcinoid.
De Jesus T; Luis SA; Ryu JH; Molina JR; Connolly HM; Maleszewski JJ; Pellikka PA
J Thorac Oncol; 2018 Oct; 13(10):1602-1605. PubMed ID: 30251640
[TBL] [Abstract][Full Text] [Related]
16. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Fust K; Maschio M; Kohli M; Singh S; Pritchard DM; Marteau F; Myrenfors P; Feuilly M
Pharmacoeconomics; 2020 Jun; 38(6):607-618. PubMed ID: 32157590
[TBL] [Abstract][Full Text] [Related]
17. First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor.
Nath E; Sawyer MB; Choy J
Case Rep Oncol; 2020; 13(3):1454-1462. PubMed ID: 33442370
[TBL] [Abstract][Full Text] [Related]
18. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.
Kiesewetter B; Duan H; Lamm W; Haug A; Riss P; Selberherr A; Scheuba C; Raderer M
Oncologist; 2019 Feb; 24(2):255-258. PubMed ID: 30171068
[TBL] [Abstract][Full Text] [Related]
19. Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Wolin EM; Benson Iii AB
Oncology; 2019; 96(6):273-289. PubMed ID: 31018209
[TBL] [Abstract][Full Text] [Related]
20. Carcinoid heart disease.
Palaniswamy C; Frishman WH; Aronow WS
Cardiol Rev; 2012; 20(4):167-76. PubMed ID: 22314145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
